Suppression of Acid Sphingomyelinase Protects the Retina from Ischemic Injury

Jie Fan,1 Bill X. Wu,2 and Craig E. Crosson1

1Storm Eye Institute, Medical University of South Carolina, Department of Ophthalmology, Charleston, South Carolina, United States
2Departments of Immunology and Microbiology, Medical University of South Carolina, Charleston, South Carolina, United States

PURPOSE. Acid sphingomyelinase (ASMase) catalyzes the hydrolysis of sphingomyelin to ceramide and mediates multiple responses involved in inflammatory and apoptotic signaling. However, the role ASMase plays in ischemic retinal injury has not been investigated. The purpose of this study was to investigate how reduced ASMase expression impacts retinal ischemic injury.

METHODS. Changes in ceramide levels and ASMase activity were determined by high performance liquid chromatography-tandem mass spectrometry analysis and ASMase activity. Retinal function and morphology were assessed by electoretinography (ERG) and morphometric analyses. Levels of TNF-α were determined by ELISA. Activation of p38 MAP kinase was assessed by Western blot analysis.

RESULTS. In wild-type mice, ischemia produced a significant increase in retinal ASMase activity and ceramide levels. These increases were associated with functional deficits as measured by ERG analysis and significant structural degeneration in most retinal layers. In ASMase−/− mice, retinal ischemia did not significantly alter ASMase activity, and the rise in ceramide levels were significantly reduced compared to levels in retinas from wild-type mice. In ASMase−/− mice, functional and morphometric analyses of ischemic eyes revealed significantly less retinal degeneration than in injured retinas from wild-type mice. The ischemia-induced increase in retinal TNF-α levels was suppressed by the administration of the ASMase inhibitor desipramine, or by reducing ASMase expression.

CONCLUSIONS. Our results demonstrate that reducing ASMase expression provides partial protection from ischemic injury. Hence, the production of ceramide and subsequent mediators plays a role in the development of ischemic retinal injury. Modulating ASMase may present new opportunities for adjunctive therapies when treating retinal ischemic disorders.

Keywords: acid sphingomyelinase, ischemia, neuroprotection, retinal degeneration, sphingolipids
tions have shown that elevation of ceramide levels occurs in various in vivo ischemia models, including heart, liver, and kidney. In the brain, the upregulation of ASMase activity is responsible for the ischemia-induced rise in astroglia ceramide levels. The extent of tissue damage in the ischemic brain, heart, and liver can be attenuated by the genetic deletion of ASMase, or in vivo administration of an ASMase inhibitor such as desipramine or short interfering RNA. Opreanu et al. provided evidence that cytokine-induced inflammatory signaling can be suppressed by down-regulating ASMase in human retinal endothelial cells. However, the role of ASMase in ischemia-induced retinal neuronal degeneration has not been investigated. The purpose of this study was to investigate whether sphingolipid signaling is involved in retinal ischemic injury and whether suppression of ASMase expression suppresses the ischemic injury.

**Materials and Methods**

**Animals**

The ASMase knockout mice on a C57/BL6 background were the generous gift of Edward H. Schuman (Icahn Medical Institute, New York, NY). Heterozygous (ASMase+/−) mice were bred and genotyped as previously described. Animals were reared under 12L:12D conditions with ambient light intensity (150 ± 20 lux). Mice 10 to 12 weeks of age were used for the experiments. Because previous studies have demonstrated that ASMase knockout mice exhibit outer retinal dysfunction and degeneration, mice were used for most of the experiments in this study. In select experiments, wild-type control mice were treated with the ASMase inhibitor desipramine (Sigma-Aldrich Corp., St. Louis, MO, USA). For those experiments, desipramine was dissolved in 1X phosphate-buffered saline (PBS; 0.8 mg/mL) and injected intraperitoneally (10 mg/kg) 1 hour before the retinal ischemia injury. Control animals were injected with an equal volume of sterile 1X PBS.

All experiments were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research; and the study protocol was approved by the MUSC Animal Care and Use Committee.

**Retinal Ischemia**

Retinal ischemia was induced using techniques described previously with minor modification. Briefly, mice were anesthetized with 500 mg/kg 1.25% Avertin solution (1.25 g 2,2,2-trifluoroethanol; Sigma-Aldrich Corp.), 2.5 mL tertiary-amyl alcohol (Sigma-Aldrich Corp.) in 100 mL PBS. Proparacaine (5 μL, 0.5%; Akorn, Inc., Buffalo Grove, IL, USA) was applied for cornea analgesia. Body temperature was maintained on a temperature-controlled heat pad (Bioanalytical System, Inc., West Lafayette, IN, USA) at 37°C during the experiment. The anterior chamber was cannulated with a 33-gauge needle (World Precision Instruments, Inc., Sarasota, FL, USA), which was connected to a reservoir of sterile PBS, pH 7.4. The container was elevated to raise the IOP to 120 mm Hg for 50 minutes. The IOP was monitored by a calibrated pressure transducer (Argon Medical Devices, Athens, TX, USA), and the absence of retinal blood flow was confirmed by direct ophthalmoscopy. The contralateral eye was untreated and served as a control. Following ischemic injury and recovery from anesthesia, the pupil light reflex was verified as present and not different from the contralateral control eye. Then the eyes were allowed to reperfuse for a different period of time depending on the experimental endpoint being evaluated. To evaluate structural and functional injury, retinas were allowed to reperfuse for 7 days. To evaluate changes in ASMase activity and TNF-α, tissues were collected at 90 minutes and 4 hours, respectively. Changes in sphingolipids were evaluated following 2 and 24 hours of reperfusion.

**Sphingolipid Analyses**

Retinas were collected in lysis buffer (50 mM Tris-base, 1.0 mM EDTA, 0.2% Triton X-100, 1X protease inhibitor, pH 7.4). These retinas were lysed by brief sonication. Tissue debris and unbroken cells were pelleted and removed by centrifugation at 300g for 5 minutes at 4°C. Cellular homogenates (0.5 mg) were used for the sphingolipid analyses, which were performed by Lipidomics Core Facility (Medical University of South Carolina, Charleston, SC, USA), using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) as previously described, using electrospray ionization/tandem mass spectrometry (ESI-MS/MS), using a triple-stage quadrupole mass spectrometer (TSQ 7000; Thermo Finnigan, San Jose, CA, USA), operating in a multiple reaction monitoring positive ionization mode as described previously.

**Electroretinograms**

Mice were dark-adapted overnight and anesthetized using xylazine (20 mg/kg, intraperitoneally) and ketamine (80 mg/kg, intraperitoneally). Pupils were dilated with phenylephrine hydrochloride (2.5%; Akorn) and atropine sulfate (1%; Bausch & Lomb, Tampa, FL, USA). Contact lens electrodes were placed on both eyes accompanied by 2.5% hypromellose ophthalmic demulcent solution (Goniovisc; HUB Pharmaceuticals, LLC, Rancho Cucamonga, CA, USA). Single white flashes (10 ms) with intensity of 2.48 cd/s/m² were used for stimulation. No frequency filtering was used. A-wave amplitudes were measured from baseline to the a-wave trough. The b-wave amplitudes were measured from the a-wave trough to the peak of the b-wave. ERGs were recorded 24 hours before the retinal ischemia and 7 days post ischemia.

**Histology**

For morphometric analyses, mouse eyes were enucleated and fixed in freshly made 4% paraformaldehyde in 0.1 M PBS for 2 hours at 4°C. After fixation, the tissues were dehydrated and embedded in paraffin. Retinal cross-sections (5 μm thick) were then cut and stained with hematoxylin and eosin (Sigma-Aldrich Corp.). Only sections through the optic nerve were used. Retinal sections were photographed and measured approximately 2 to 3 disc diameters from the optic nerve, using an Axiosplan II microscope (Carl Zeiss, Inc., Germany) and a 20× objective lens. The number of cells in the retinal ganglion cell layer was determined by cell counts over a distance scale of 200 μm. Morphologic values for each retina were determined from three sections for each eye, and n ≥6 eyes were included for each group.

**ASMase Activity Assay**

Retinas were isolated 90 minutes after the ischemic injury, and lysed in lysis buffer (50 mM sodium acetate, 1 mM EDTA, 1% Triton X-100, protease inhibitor cocktail, pH 5.0) by brief sonication. The lysates were centrifuged at 12,000g for 4 minutes, and the supernatants were used for measuring ASMase activity by using commercial Amplex Red sphingomyelinase assay kit following the manufacturer's instruction
The samples or negative controls were incubated with 10 μM of the 5 mM sphingomyelin solution for 1 hour at 37°C, protected from light; then working solution of 100 μM Amplex Red reagent containing 2 U/mL horseradish-peroxidase, 0.2 U/mL choline oxidase, and 8 U/mL alkaline phosphatase, was added and incubated for 2 hours. Fluorescence was measured using a fluorescence microplate reader at excitation of 530 nm and emission detection at 590 nm. The actual readings were corrected for background fluorescence by subtracting the values derived from the negative control and normalized to protein levels.

**TNF-α Analysis**

Retinas were collected at 4 hours after ischemia, and retina extracts were used to measure TNF-α by commercial ELISA kits following the manufacturer's instruction (eBioscience, San Diego, CA, USA). Briefly, retina extracts were incubated in...
96-well plates coated with monoclonal antibody specific for mouse TNF-α. After washing, biotin-conjugated anti-mouse TNF-α (polyclonal) and avidin-horseradish peroxidase antibodies were added and incubated in accordance with the manufacturer’s instructions. After washing, a substrate solution was added to each well. The enzyme reaction was ended by adding stop solution. Absorbance was measured at 450 nm. Using a standard curve prepared from different dilutions of recombinant TNF-α standard, we calculated each concentration of TNF-α for the retina extracts.

**Cell Culture**

The primary human optic nerve head astrocytes were isolated and cultured as previously described. Prior to the study, confluent astrocyte cultures were serum-starved overnight and pretreated with desipramine (20 µM; Sigma-Aldrich Corp.) or vehicle for 1 hour. Cells were then treated with TNF-α (10 ng/mL; R&D System, Inc., Minneapolis, MN, USA) for 15 minutes.

**Western Blotting**

Following the treatment period, cells were harvested and homogenized in lysis buffer (50 mM Tris-base; 10 mM EDTA; 0.5 mM sodium orthovanadate; 0.5% sodium deoxycholic acid; 1% Triton X-100 and protease inhibitor cocktail (Roche Diagnostics Corp., Indianapolis, IN, USA); pH 7.4). Equal amounts of total protein from each lysate were loaded onto NuPAGE Novex 4-12% bis-Tris protein gels (Life Technologies Corp., Carlsbad, CA, USA) and subjected to Western blot analysis using primary antibodies, followed by horseradish-peroxidase-labeled secondary antibody (1:5000 dilution, Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The signals were detected using enhanced chemoluminescence reagents (Thermo Scientific, Waltham, MA, USA). The primary antibodies against p-p38 (1:1000 dilution) and p38 antibody (1:1000 dilution) were purchased from Cell Signaling Technology (Danvers, MA, USA). β-Actin antibody (1:2000 dilution) was purchased from Sigma-Aldrich Corp.

**Statistics**

For all experiments, data are mean ± SEM. Data were analyzed using a 2-tailed Student’s t-test or ANOVA. A P value < 0.05 was considered significant.

**RESULTS**

**Effect of Retinal Ischemia on Sphingolipid Profile**

To investigate whether acute retinal ischemic injury could alter the sphingolipid profile, retinas were isolated 2 or 24 hours after ischemia, and homogenates were analyzed by mass spectrophotometry. As shown in Figure 1A, 2 hours after ischemic injury, the ceramide levels were elevated in ischemic retinas (Fig. 1, black bars) compared with the contralateral retinas (Fig. 1, white bars). Ceramide lipids (C14-Cer, C16-Cer, C18-Cer, C18:1-Cer, C26-Cer, dehydro C16-Cer) and sphingosine displayed significant increases (*P* < 0.05). Among these ceramides, C16-Cer, C18-Cer, and C20-Cer were the dominant retinal forms and exhibited robust elevations (110.5 ± 19.3%, 107.1 ± 38.0%, and 145.8 ± 19.9%, respectively) following ischemic injury. No significant changes were detected in the sphingomyelin profile between contralateral and ischemic retinas (Fig. 1B). The elevation of ceramide was maintained up to 24 hours postischemic injury, and no significant differences in total ceramide levels were measured between 2 and 24 hours (Fig. 2). A comparison of retinal ceramide levels from contralateral eyes of wild-type mice with those of

**ASMase Inhibition Prevents Retinal Ischemic Injury**

Figure 3. Ceramide profile in ASMase+/+ and ASMase−/− retinas in control and ischemic retinas 2 hours after the ischemic injury. Inset presents the total ceramide level in ASMase+/+ and ASMase−/− retinas. Data are mean ± SEM; n = 4. *Significant differences from ASMase−/− control to wild-type contralateral eyes (*P* < 0.05); **Significant differences from ASMase−/− ischemic eyes to wild-type ischemic eyes.

**Figure 4.** Effect of retinal ischemia on ASMase activity changes in ASMase+/+ (black) and ASMase−/− (white) retinas before and 90 minutes after the retinal ischemic injury. Data are mean ± SEM; n = 4. *P* < 0.05.
ASMase\(^{+/+}\) mice demonstrated that total retinal ceramide in ASMase\(^{+/+}\) retinas was significantly lower than that in wild-type mice. This reduction was primarily due to the reduction in isoforms C16-Cer and C18-Cer (Fig. 3). Analysis of retinas from ASMase\(^{+/+}\) mice 2 hours following ischemic injury demonstrated that the ischemia-induced rise in total ceramide and individual isoforms (C16-Cer, C18-Cer, C18:1-Cer, and C20-Cer) were significantly reduced compared to the ischemic retinas from wild-type mice (Fig. 3).

To determine whether ischemia alters retinal ASMase activity, retinas from both the wild-type and the ASMase\(^{+/+}\) mice were isolated 90 minutes after ischemia. In wild-type mice, ischemia induced a 29.8% increase in ASMase activity compared with retinas from contralateral eyes. In control retinas from ASMase\(^{+/+}\) mice, ASMase activity was reduced by 35 ± 7.8% compared to that in the corresponding retinas from wild-type mice (Fig. 4). No increase in retinal ASMase activity was measured in the ASMase\(^{+/+}\) mice following ischemia.

**Effect of Reduced ASMase Expression on Retinal Ischemic Injury**

In wild-type mice (\(n = 5\)), baseline ERG a- and b-wave amplitudes were 309.9 ± 17.9 and 584.54 ± 28.8 \(\mu\)V, respectively. In ASMase\(^{+/+}\) mice (\(n = 8\)), baseline ERG amplitudes (a-wave: 321.0 ± 10.5; and b-wave: 583.8 ± 18.7 \(\mu\)V) were not significant from amplitudes measured in wild-type mice. Seven days postischemic injury, wild-type mice exhibited a significant decrease in mean a- and b-wave amplitudes from baseline levels of 61 ± 0.9% and 61 ±
Hence, the differences in contrast to that in wild-type mice demonstrated that the thickness of cell bodies from the ganglion cell layer (Table). In wild-type mice, ischemia induced a 3.2-fold increase in TNF-α levels compared to the levels measured in the contralateral retinas (Fig. 7). Although TNF-α levels also increased in ischemic ASMSas+/− retinas, those levels were significantly lower than wild-type and ASMSas+/− mice were measured at study day 7 (Fig. 5).

**Effect of Reduced ASMSas Expression on Inflammatory Signaling**

Retinas were collected at 4 hours after ischemia, and retinal TNF-α levels were determined by ELISA. In retinas from wild-type mice, ischemia induced a 3.2-fold increase in TNF-α levels also increased in ischemic ASMSas+/− retinas, those levels were significantly lower than

**TABLE. Analyses of Contralateral and Ischemic Retinas in Wild-Type and ASMSas+/− Mice**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Contralateral</th>
<th>ASMSas+/−</th>
<th>Ischemia</th>
<th>ASMSas+/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retina thickness, µm</td>
<td>144.9 ± 6.1</td>
<td>147.3 ± 7.5</td>
<td>111.0 ± 5.3*</td>
<td>132.5 ± 2.9†‡</td>
</tr>
<tr>
<td>PR thickness, µm</td>
<td>30.3 ± 1.3</td>
<td>32.1 ± 1.8</td>
<td>22.6 ± 2.8*</td>
<td>28.9 ± 2.9</td>
</tr>
<tr>
<td>ONL thickness, µm</td>
<td>35.6 ± 1.5</td>
<td>39.4 ± 1.1</td>
<td>35.9 ± 2.4</td>
<td>38.7 ± 1.5</td>
</tr>
<tr>
<td>INL thickness, µm</td>
<td>23.6 ± 1.1</td>
<td>24.4 ± 1.4</td>
<td>18.9 ± 1.5*‡</td>
<td>22.3 ± 1.0†</td>
</tr>
<tr>
<td>IPL thickness, µm</td>
<td>45.9 ± 2.9</td>
<td>46.6 ± 3.0</td>
<td>22.1 ± 4.0*‡</td>
<td>35.6 ± 3.2†‡</td>
</tr>
<tr>
<td>GCL, Soma per 200 µm</td>
<td>19.9 ± 0.5</td>
<td>19.9 ± 0.6</td>
<td>9.7 ± 1.1*‡</td>
<td>16.0 ± 0.8†‡</td>
</tr>
</tbody>
</table>

Data are mean ± SEM; n ≥ 6. GCL, ganglion cell layer; INL, inner nuclei layer; IPL, inner plexiform layer; ONL, outer nuclei layer; PR, photo receptor.

* Significant differences (P < 0.05) between ischemic eyes and contralateral retinas in wild-type (WT) mice.
† Significant differences (P < 0.05) between ischemic eyes and contralateral retinas in ASMSas+/− mice.
‡ Significant differences (P < 0.05) between ischemic wild-type and ASMSas+/− retinas.

**FIGURE 6.** Effect of ASMSas inhibition on retinal morphology change after retinal ischemic injury. Images of representative retina cross-sections of contralateral eyes and ischemic eyes from ASMSas+/− and ASMSas+/− mice. All images were taken 2 to 3 disc diameters from the optic nerve.

**FIGURE 7.** Measurement of TNF-α levels in contralateral and ischemic retinas from ASMSas+/− and ASMSas+/− mice and desipramine-treated ASMSas+/− mice by ELISA. Data are mean ± SEM; n = 4. *P < 0.05.
the levels from ischemic wild-type retinas. In the wild-type mice, administration of the ASMase inhibitor desipramine (10 mg/kg) significantly suppressed the ischemia-induced rise in TNF-α levels by 52 ± 12.4% compared to the ischemic retinas from control mice.

Astrocytes play a major role in modulating ischemic retinal injury. Hence, cultured primary human astrocytes, derived from the optic nerve head, were utilized to assess the involvement of ASMase on activation (phosphorylation) on the stress-activated MAP kinase, p38. Astrocyte cultures treated with TNF-α (10 ng/mL) for 15 minutes exhibited a significant increase in p38 phosphorylation over the control level (Fig. 8). This increase in p38 phosphorylation was significantly reduced in cultures pretreated (15 minutes) with the ASMase inhibitor, desipramine (20 μM). Treatment of astrocytes with desipramine alone did not significantly alter the levels of p38 phosphorylation.

**DISCUSSION**

Ceramides are a family of bioactive lipid molecules, which have been shown to modulate many physiological functions. In addition, these lipids have been shown to contribute to the pathogenesis of various cancers, diabetes, obesity, inflammatory conditions, microbial infections, and neurodegenerative disorders. One of the most studied roles of ceramides is their function as proapoptotic molecules. Several in vivo ischemia-reperfusion models have provided evidence that ceramides can contribute to the apoptotic process.

The endogenous levels and turnover of the sphingolipid molecules are regulated by multiple enzymes and pathways. Ceramides can be produced through multiple mechanisms including hydrolysis of sphingomyelin by sphingomyelinase, de novo synthetic and salvage pathways. In the normal nonischemic retina, the three dominant ceramides are C16, C18, and C20 (Fig. 1).

In the current study, we found that acute retinal ischemic injury significantly increased the ceramide levels as early as 2 hours after injury and that these levels remained elevated up to 24 hours post ischemia. As shown in Figure 3, the increase in ceramides was dependent on the normal expression of ASMase. However, we did not measure any significant changes in the level of sphingomyelins following ischemic injury. Stress-induced elevations in ceramides, in the absence of measurable reductions in sphingomyelin levels, can indicate an increase in the de novo pathway activity. However, in tissues where the sphingomyelin-to-ceramide ratio is high (e.g., 10:1), ASMase-dependent increases in ceramide levels have been measured without corresponding significant reductions in sphingomyelin. Hence, in the retina, sphingomyelins-to-corresponding ceramide ratios ranged from 12:1 to 122:1 based on our sphingolipid profiles (Fig. 1). Hence, significant increases in the ceramide production via ASMase hydrolysis can likely occur without significantly reducing the levels of sphingomyelin. Overall, our results provide evidence that the ischemia-induced increase in ceramides is dependent upon ASMase hydrolysis; however, the involvement of the de novo and salvage pathways in this increase cannot be completely discounted. It should also be noted that activation of ASMase has been linked to ischemic brain injury. Hence, understanding all the pathways that contribute to the rise in ceramides observed in ischemic retinas from ASMase−/− mice will require additional study.

Previous studies in the brain have demonstrated that ASMase plays a critical role in ischemia-induced cytokine production and neuronal apoptosis and that ASMase inhibition can reduce both inflammation and apoptosis. Mechanistic studies have shown that ASMase can regulate both cytokine production and p38 MAPK activation. However, the ability of ASMase to influence p38 signaling is not observed in all cells. Our results demonstrated that ischemic retinal injury in wild-type mice increased the levels of ceramides and TNF-α and that by comparison both responses were suppressed in retinas from ASMase−/− mice. Using cultured astrocytes, we demonstrated that the ASMase inhibitor desipramine also blocked the TNF-α-induced activation of p38 MAP kinase, revealing a critical role for ASMase in TNF-α signaling in astrocytes. Although the underlying mechanisms regarding how ASMase modulates these signals in astrocytes will require additional investigations, these mechanisms may include the transactivation of cytokines (e.g., IL-1β or IL-6) potentiates the activation of ASMase-dependent sphingolipid signaling and ultimately results in autocrine activation by sphingosine-1-phosphate. Despite the complexities of retinal sphingolipid metabolism, our results support the idea that the increased ceramide levels contribute to inflammatory signaling in the ischemic retina and the resulting neurodegenerative response to ischemia is due to the increased ASMase activity and/or expression.

To investigate whether reduced expression of ASMase provides functional and structural protection of the retina, wild-type and ASMase−/− mice received unilateral ischemic retinal injury and allowed to recover for seven days. As shown in Figure 5, ERG responses from wild-type mice 7 days post injury exhibited mean deficits in a- and b-wave amplitudes of 61 ± 0.9% and 61 ± 12.3%, respectively. In ASMase−/− mice that received unilateral ischemic retinal injury, ERG a- and b-wave amplitudes exhibited significant declines compared to contralateral (nonischemic) eyes; however, these reductions were significantly less than those measured in wild-type mice.
However, it should be noted that using contralateral eyes as controls may obscure contralateral changes resulting from ipsilateral retinal and optic nerve degeneration. Morphologic measurements demonstrated that ischemic injury produced significant degeneration in most retinal layers; however, this degenerative response was also significantly reduced in ASMase−/− mice. These results are consistent with the idea that suppressing ASMase activity can provide structural and functional protection from ischemic injury.

Finally, it should also be noted that wild-type mice used in these studies exhibited greater a-wave deficits than those observed in previous studies without corresponding increases in photoreceptor degeneration.64 These results provide evidence that maintaining photoreceptor architecture is not sufficient to preserve photoreceptor function and that the C57/BL6 is functionally more sensitive to ischemic injury than previous mouse strains evaluated by this laboratory.64

In summary, studies in brain, heart, liver, and kidney have shown that the activation of ASMase is an early event in apoptotic and necrotic processes.15 The current study revealed that acute retinal ischemia results in the rapid increase in ASMase activity leading to a rise in the levels of multiple ceramides, the secretion of TNF-α and eventual retinal degeneration. In addition, we found that reducing ASMase expression suppressed this sequelae of events and partially protected the retina from retinal ischemic injury. These results provided evidence that sphingolipid metabolism plays an important role in the development of ischemic retinal injury. Hence, the identifying strategies to inhibit ASMase may provide new opportunities to treat ischemic retinal disorders in adults.

Acknowledgments

The authors thank Luanna Bartholomew, PhD, for critical review of the manuscript. Supported by U.S. National Institutes of Health grant EY021568 (CEC), an unrestricted grant to Department of Ophthalmology, Medical University of South Carolina (MUSC), from Research to Prevent Blindness; Lipidomics Shared Resource, Hollings Cancer Center, MUSC grant P30 CA138313; Lipidomics Core, SC Lipidomics and Pathobiology Center of Biomedical Research Excellence, Department of Biochemistry, MUSC grant P20 RR017677; and National Center for Research Resources and Office of the Director of the NIH grant C06 RR018823.

Disclosure: J. Fan, None; B.X. Wu, None; C.E. Crosson, None

References


